Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Immunol ; 50(2): 178-191, 2020 02.
Article in English | MEDLINE | ID: mdl-31608441

ABSTRACT

Mucosal associated invariant T (MAIT) cells are abundant unconventional T cells that can be stimulated either via their TCR or by innate cytokines. The MAIT cell TCR recognises a pyrimidine ligand, derived from riboflavin synthesising bacteria, bound to MR1. In infection, bacteria not only provide the pyrimidine ligand but also co-stimulatory signals, such as TLR agonists, that can modulate TCR-mediated activation. Recently, type I interferons (T1-IFNs) have been identified as contributing to cytokine-mediated MAIT cell activation. However, it is unknown whether T1-IFNs also have a role during TCR-mediated MAIT cell activation. In this study, we investigated the co-stimulatory role of T1-IFNs during TCR-mediated activation of MAIT cells by the MR1 ligand 5-amino-6-d-ribitylaminouracil/methylglyoxal. We found that T1-IFNs were able to boost interferon-γ and granzyme B production in 5-amino-6-d-ribitylaminouracil/methylglyoxal-stimulated MAIT cells. Similarly, influenza virus-induced T1-IFNs enhanced TCR-mediated MAIT cell activation. An essential role of T1-IFNs in regulating MAIT cell activation by riboflavin synthesising bacteria was also demonstrated. The co-stimulatory role of T1-IFNs was also evident in liver-derived MAIT cells. T1-IFNs acted directly on MAIT cells to enhance their response to TCR stimulation. Overall, our findings establish an important immunomodulatory role of T1-IFNs during TCR-mediated MAIT cell activation.


Subject(s)
Interferon Type I/immunology , Mucosal-Associated Invariant T Cells/immunology , Receptors, Antigen, T-Cell/immunology , Cells, Cultured , Cytokines/immunology , Humans , Immunity, Innate/immunology , Interferon-gamma/immunology , Ligands , Lymphocyte Activation/immunology
2.
Future Microbiol ; 12: 817-829, 2017 07.
Article in English | MEDLINE | ID: mdl-28593794

ABSTRACT

Chlamydia trachomatis is the most prevalent sexually transmitted bacterial infection worldwide and the leading cause of preventable blindness. Reports have emerged of treatment failure, suggesting a need to develop new antibiotics to battle Chlamydia infection. One possible candidate for a new treatment is the protease inhibitor JO146, which is an effective anti-Chlamydia agent that targets the CtHtrA protein. CtHtrA is a lynchpin on the chlamydial cell surface due to its essential and multifunctional roles in the bacteria's stress response, replicative phase of development, virulence and outer-membrane protein assembly. This review summarizes the current understanding of CtHtrA function and presents a mechanistic model that highlights CtHtrA as an effective target for anti-Chlamydia drug development.


Subject(s)
Chlamydia Infections/drug therapy , Chlamydia trachomatis/enzymology , Serine Endopeptidases/metabolism , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Bacterial Outer Membrane Proteins/chemistry , Bacterial Outer Membrane Proteins/metabolism , Chlamydia Infections/microbiology , Chlamydia trachomatis/drug effects , Chlamydia trachomatis/metabolism , Chlamydia trachomatis/pathogenicity , Dipeptides/therapeutic use , Humans , Models, Biological , Models, Molecular , Organophosphonates/therapeutic use , Protease Inhibitors/pharmacology , Protease Inhibitors/therapeutic use , Serine Endopeptidases/chemistry , Serine Endopeptidases/genetics , Virulence Factors/chemistry , Virulence Factors/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...